123 related articles for article (PubMed ID: 8684530)
21. Use of ultrafiltration and chromatography to assess aluminum speciation in serum after deferoxamine administration.
Canteros-Picotto A; Fernández-Martín JL; Cannata-Andía JB
Am J Kidney Dis; 2000 Nov; 36(5):969-75. PubMed ID: 11054353
[TBL] [Abstract][Full Text] [Related]
22. Treatment of aluminum overload using a cartridge with immobilized desferrioxamine.
Anthone S; Ambrus CM; Kohli R; Min I; Anthone R; Stadler A; Stadler I; Vladutiu A
J Am Soc Nephrol; 1995 Oct; 6(4):1271-7. PubMed ID: 8589296
[TBL] [Abstract][Full Text] [Related]
23. Studies of variations of subcutaneously infused desferrioxamine and iron movements in thalassaemia children.
Llados i Vallory EA; Girot R; Lenoir G; Payet M; Houze P; Bourdon R
Eur J Pediatr; 1989 Apr; 148(6):503-6. PubMed ID: 2744011
[TBL] [Abstract][Full Text] [Related]
24. Aluminum accumulation in children on chronic dialysis: predictive value of serum aluminum levels and desferrioxamine infusion test.
Roodhooft AM; van de Vyver FL; D'Haese PC; van Acker KJ; Visser WJ; de Broe ME
Clin Nephrol; 1987 Sep; 28(3):125-9. PubMed ID: 3665205
[TBL] [Abstract][Full Text] [Related]
25. Red blood cell aluminum in patients with renal failure and effect of desferrioxamine infusion.
Umeda M; Tsurusaki K; Kamikawa S; Izumi N; Yasumoto R; Kishimoto T; Maekawa M
Blood Purif; 1990; 8(5):295-300. PubMed ID: 2091689
[TBL] [Abstract][Full Text] [Related]
26. Therapy and monitoring of hypersiderosis in chronic renal insufficiency.
Hilfenhaus M; Koch KM; Bechstein PB; Schmidt H; Fassbinder W; Baldamus CA
Contrib Nephrol; 1984; 38():167-74. PubMed ID: 6713893
[TBL] [Abstract][Full Text] [Related]
27. Failure of deferoxamine to improve iron overload in chronic hemodialysis patients.
Roxe DM; Krumlovsky FA; Del Greco F; Fitzsimons E
Int J Artif Organs; 1990 Apr; 13(4):211-7. PubMed ID: 2115505
[TBL] [Abstract][Full Text] [Related]
28. Clinical experience with desferrioxamine in dialysis patients with aluminium toxicity.
McCarthy JT; Milliner DS; Johnson WJ
Q J Med; 1990 Mar; 74(275):257-76. PubMed ID: 2117295
[TBL] [Abstract][Full Text] [Related]
29. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
30. Plasma aluminum and iron kinetics in hemodialyzed patients after i.v. infusion of desferrioxamine.
Ciancioni C; Poignet JL; Mauras Y; Panthier G; Delons S; Allain P; Man NK
Trans Am Soc Artif Intern Organs; 1984; 30():479-82. PubMed ID: 6533925
[No Abstract] [Full Text] [Related]
31. Treatment of iron overload in children and adolescents on chronic haemodialysis.
Eijgenraam FJ; Donckerwolcke RA
Eur J Pediatr; 1990 Feb; 149(5):359-62. PubMed ID: 2311634
[TBL] [Abstract][Full Text] [Related]
32. The transport of two iron chelators, desferrioxamine B and L1, across Caco-2 monolayers.
Hamilton KO; Stallibrass L; Hassan I; Jin Y; Halleux C; Mackay M
Br J Haematol; 1994 Apr; 86(4):851-7. PubMed ID: 7918082
[TBL] [Abstract][Full Text] [Related]
33. Recombinant human erythropoietin resistance in iron-replete hemodialysis patients: role of aluminum toxicity.
Tarng DC; Huang TP
Am J Nephrol; 1998; 18(1):1-8. PubMed ID: 9481432
[TBL] [Abstract][Full Text] [Related]
34. Iron removal by desferrioxamine in patients on chronic hemodialysis--kinetic study and long-term results.
Kovarik J; Irschik H; Graf H; Woloszczuk W; Meisinger V; Linkesch W; Stummvoll HK
Contrib Nephrol; 1985; 49():44-55. PubMed ID: 3830570
[TBL] [Abstract][Full Text] [Related]
35. Continuous ambulatory EEG monitoring following desferrioxamine (DFO) i.v. infusion.
Poignet JL; Monge MF; Ciancioni C; Mikol F; Naret C; Delons S; Man NK
Trans Am Soc Artif Intern Organs; 1985; 31():546-51. PubMed ID: 3837504
[No Abstract] [Full Text] [Related]
36. Comparative study of intravenous ascorbic acid versus low-dose desferroxamine in patients on hemodialysis with hyperferritinemia.
Deira J; Diego J; Martínez R; Oyarbide A; González A; Díaz H; Grande J
J Nephrol; 2003; 16(5):703-9. PubMed ID: 14733417
[TBL] [Abstract][Full Text] [Related]
37. Detoxification in hemosiderosis.
Simon P
Blood Purif; 1985; 3(1-3):75-88. PubMed ID: 3913449
[TBL] [Abstract][Full Text] [Related]
38. Aluminum removal with hemodialysis, hemofiltration and charcoal hemoperfusion in uremic patients after desferrioxamine infusion. A comparison of efficiency.
Weiss LG; Danielson BG; Fellström B; Wikström B
Nephron; 1989; 51(3):325-9. PubMed ID: 2918944
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics and renal elimination of desferrioxamine and ferrioxamine in healthy subjects and patients with haemochromatosis.
Allain P; Mauras Y; Chaleil D; Simon P; Ang KS; Cam G; Le Mignon L; Simon M
Br J Clin Pharmacol; 1987 Aug; 24(2):207-12. PubMed ID: 3620295
[TBL] [Abstract][Full Text] [Related]
40. [The causes, diagnosis and treatment of aluminum toxicity in patients with chronic renal failure undergoing dialysis].
Wang G; Zhu P; Wang S
Zhonghua Nei Ke Za Zhi; 1996 Jan; 35(1):36-40. PubMed ID: 9275645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
